Aspira, a bio-analytical based women’s health company focused on gynecologic disease, has announced plans to raise $45 million through a public offering of common stock. The company intends to use the net proceeds from the offering for sales and marketing, working capital and other general corporate purposes, including investing in additional key strategic hires, product portfolio expansion and research and development. Aspira may also use a portion of the net proceeds from the offering to acquire or invest in complimentary businesses, technologies, product candidates or other intellectual property, although Aspira has no present commitments or agreements to do so.
Aspira has announced the pricing of the underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Aspira has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Aspira.